Evaluating Interventional Radiology for Cancer Pain Management (RI-LieF)

April 13, 2026 updated by: Hospices Civils de Lyon

Evaluation of the Efficacy of Interventional Radiology in the Management of Pain in Patients With Cancer

Each year, the number of new cancer cases increases globally and the associated pain remains a major concern. The scientific literature shows that the prevalence and severity of cancer-related pain have decreased thanks to new therapeutic strategies and the efficacy of innovative treatments. Nevertheless, recent studies indicate that the prevalence of pain in patients with locally advanced or metastatic cancer remains high.

Cancer-related pain presents various characteristics, both in terms of timing (inflammatory and mechanical) and types (nociceptive, neuropathic, mixed, or visceral). This diversity in presentation and pathophysiology makes the condition complex, both in terms of symptom assessment and therapeutic management, requiring a multidisciplinary and often multimodal approach.

In addition to pharmacological approaches, several non-pharmacological techniques are used for this purpose, as the interventional radiology (IR), so-called minimally invasive technique. The role of IR is becoming increasingly important in pain management, particularly in the context of a growing number of cancer survivors, improved survival in the metastatic setting and the limited effectiveness of opioids. These techniques include neurolysis, embolization, consolidation techniques, ablation, and percutaneous cervical cordotomy.

The objective of the RI-Lief study is to evaluate the impact of interventional radiology on improving the quality of life of patients with locally advanced or metastatic cancer.

As part of the study, interventional radiology will be included in the standard patient care. The only additional procedure introduced by the research is the administration of questionnaires.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

125

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adult patient (age > 18 years);
  • Patient with locally advanced or metastatic cancer undergoing active management, including palliative care;
  • Patient with a clinically estimated life expectancy of at least 3 months;
  • Patient receiving treatment with chemotherapy, immunotherapy, targeted therapy, hormone therapy, or any other type of treatment for locally advanced or metastatic cancer;
  • Patient undergoing an interventional radiology procedure for pain relief (including cases where pain relief is not the primary objective);
  • Patient able to complete the proposed questionnaires.

Exclusion Criteria:

  • Patient with cancer in remission;
  • Patient with cured cancer;
  • Patient under routine follow-up.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Self-reported questionnaires
Self-reported questionnaires will be used to assess the patient's pain (using a Numerical Rating Scale and Neuropathic Pain Symptom Inventory), satisfaction with pain management (Pain Treatment Satisfactory Scale) and the global quality of life : EORTC QLQ-C30 questionnaire ( (European Organisation for Research and Treatment of Cancer (EORTC); Quality of Life Questionnaire (QLQ) Core30 (C30))
Other: Self-reported questionnaires
Self-reported questionnaires will be used to assess the patient's pain (using a Numerical Rating Scale and Neuropathic Pain Symptom Inventory), satisfaction with pain management (Pain Treatment Satisfactory Scale) and the global quality of life (EORTC QLQ-C30 questionnaire)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in pain intensity measured on a numerical scale before the interventional radiology procedure, and at 7 days, 1 month, and 3 months afterward.
Time Frame: Baseline, 7 days, 1 month and 3 months after the radiology intervention.
To evaluate the efficacy of interventional radiology for pain relief in improving pain intensity in patients with locally advanced or metastatic cancer.
Baseline, 7 days, 1 month and 3 months after the radiology intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospices Civils de Lyon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

September 1, 2028

Study Registration Dates

First Submitted

April 2, 2026

First Submitted That Met QC Criteria

April 13, 2026

First Posted (Actual)

April 14, 2026

Study Record Updates

Last Update Posted (Actual)

April 14, 2026

Last Update Submitted That Met QC Criteria

April 13, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 69HCL25_1073

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metastatic Cancer

Clinical Trials on Self-reported questionnaires

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe